Article info

Download PDFPDF

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

Authors

  • Jason M. Redman Genitourinary Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10 Center Dr., Room B2L312 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • Seth M. Steinberg Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10 Center Dr. 20892 Bethesda MD USA Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 9609 Medical Center Drive, Room 2W334, MSC 9716 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • James L. Gulley Genitourinary Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10 Center Dr., Room B2L312 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  1. a Jason.Redman{at}nih.gov
  2. b 240-276-5563
  3. c gulleyj{at}mail.nih.gov
View Full Text

Citation

Redman JM, Steinberg SM, Gulley JL
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

Publication history

  • Received May 31, 2018
  • Accepted September 10, 2018
  • First published September 18, 2018.
Online issue publication 
September 18, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.